Pancreatic Cancer Research

ResearcherIuliu Hațieganu University of Medicine and PharmacyActive in the last 2 years

Nadim Al Hajjar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5986-1233; OpenAlex author ID A5004324229, A5113903808. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 5 papers · 2023: none · 2024: 2 papers · 2025: none · 2026: 4 papers

Papers 13

  1. Mismatch Repair Protein and Microsatellite Instability Analysis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm15041411↗
  2. Pattern of HER2 and HER3 Overexpression in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/medicina62020251↗
  3. Discovery of a Secretory Granule Lumen-Enriched Serum Protein Signature in Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/medicina62030605↗
  4. Neoadjuvant Treatment Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma-A Systematic Review and Meta-Analysis of Randomized Controlled Tri… Last author DOI 10.3390/medicina62061049↗
  5. Impact on Long-term Survival of a Standardized Histopathological Protocol on the R1 Incidence in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21614/chirurgia.2024.v.119.i.2.p.171↗
  6. Changes in Pancreatic Cancer Management and Surgical Treatment During the COVID-19 Pandemic. Co-author DOI 10.3390/medicina60121924↗
  7. The role of systemic immuno-inflammatory factors in resectable pancreatic adenocarcinoma: a cohort retrospective study. Last author DOI 10.1186/s12957-022-02606-1↗
  8. Duodenopancreatectomy for PDAC Associated with MALS: A Case Report. Last author DOI 10.21614/chirurgia.2757↗
  9. The Role of Radio-Frequency and Stereotactic Ablation in the Treatment of Pancreatic Cancer. Co-author DOI 10.21614/chirurgia.2759↗
  10. Pancreatic Adenocarcinoma Associated to Intraductal Papillary Mucinous Neoplasia: Histopathological Particularities and Clinical Implications. Last author DOI 10.21614/chirurgia.2760↗
  11. Perioperative Management of Patients with Pancreatic Cancer - the ERAS Protocols. Last author DOI 10.21614/chirurgia.2761↗
  12. Synchronous Pancreatic Tumours: Intraductal Papillary Mucinous Neoplasm with Pancreatic Ductal Adenocarcinoma and Neuroendocrine Tumour: A Case Presentation an… Last author DOI 10.21614/chirurgia.116.ec.2425↗
  13. Role of computer tomography and endoscopic ultrasonography in assessing portal and superior mesenteric vessels invasion in cephalo-pancreatic adenocarcinoma. Co-author PMID 29051395↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrada Seicean · 5 shared papers, 2017–2026 · strength 0.97
  2. Emil Ioan Moiș · 4 shared papers, 2022–2026 · strength 0.86
  3. Diana Schlanger · 4 shared papers, 2021–2022 · strength 0.76
  4. Raluca Bodea · 4 shared papers, 2017–2026 · strength 0.73
  5. Ion Cosmin Puia · 4 shared papers, 2022–2024 · strength 0.71
  6. Răzvan Alexandru Ciocan · 3 shared papers, 2022–2026 · strength 0.68
  7. Septimiu Alex Moldovan · 3 shared papers, 2022–2026 · strength 0.59
  8. Radu Vidra · 2 shared papers, 2026 · strength 0.54
  9. Ioan Cătălin Bodea · 2 shared papers, 2026 · strength 0.52
  10. Aida Puia · 2 shared papers, 2024 · strength 0.40
  11. Traian Adrian Duse · 1 shared paper, 2026 · strength 0.27
  12. Cristina Adela Iuga · 1 shared paper, 2026 · strength 0.25
  13. Cornel Iancu · 2 shared papers, 2017–2024 · strength 0.25
  14. Ioana Iancu · 1 shared paper, 2022 · strength 0.14
  15. Claudiu-Iulian Bădulescu · 1 shared paper, 2022 · strength 0.14
  16. Constantin Iordache · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.